Skip to main content

Table 1 NF-κBp65 tissue homogenate level (ng/ml), serum level of Bcl-2 (U/ml) and IL-6 (pg/ml)

From: Role of chronic E. coli infection in the process of bladder cancer- an experimental study

Group

NF-κBp65 (ng/ml)

Bcl-2 (U/ml)

IL-6 (pg/ml)

  

3 months

6 months

9 months

3 months

6 months

9 months

3 months

6 months

9 months

Group I

Range

0.51- 0.67

0.51-0.75

0.60-0.87

293.30- 331.94

310.74-331.94

305.78- 348.24

12.65-15.20

13.55-16.95

14.5-17.00

 

Mean ± S.D

0.57 ± 0.07

0.61 ± 0.08

0.70 ± 0.11

309.14 ± 14.55

320.61 ± 7.47

323.47 ± 14.33

14.09 ± 0.87

14.74 ± 1.23

15.63 ± 0.89

Group II

Range

0.52-1.13

0.91- 1.145

1.13-1.74

329.75-396.42

412.63-584.94

354.27- 681.57

17.77-22.44

20.91-25.11

24.76-29.69

 

Mean ± S.D

0.92 ± 0.22a,d

1.11 ± 0.19a,d

1.30 ± 0.22a,c,d

354.74 ± 23.44a,d

485.36 ± 60.12a,c,d

485.58 ± 120.36a

19.76 ± 1.64a,d

23.13 ± 1.46 a,d

26.41 ± 1.89a,d

Group III

Range

0.57- 1.05

1.02-1.50

1.39- 2.09

315.83-351.77

341.94-374.09

362.57-407.20

17.22-21.78

20.08-24.22

22.50-25.59

 

Mean ± S.D

0.84 ± 0.17a,d

1.27 ± 0.20a,d

1.66 ± 0.27a,b

331.78 ± 11.86 a,d

361.59 ± 11.95a,b,d

386.92 ± 19.14a,d

19.21 ± 1.56a,d

22.29 ± 1.48 a,d

24.37 ± 1.32a,d

Group IV

Range

0.94- 1.40

1.30-1.87

1.58-1.95

377.06-399.89

484.65-595.49

522.07- 726.57

22.00-27.46

26.61-34.78

35.87-43.51

 

Mean ± S.D

1.19 ± 0.19a,b,c

1.52 ± 0.21a,b,c

1.72 ± 0.14a,b

387.05 ± 8.40a,b,c

544.54 ± 37.11a,b,c

592.60 ± 75.22a,c

24.80 ± 2.20a,b,c

30.66 ± 3.20a,b,c

40.55 ± 2.69a,b,c

  1. Group I: Control group; Group II: E. coli group; Group III: Nitrosamine precursor group; Group IV: E. coli and nitrosamine precursor; a: Significantly different from control group (group I) at P<0.05; b: Significantly different from E. coli group (group II) at P<0.05; c: Significantly different from nitrosamine precursors group (group III) at P<0.05; d: Significantly different from E. coli  + nitrosamine precursors group (group IV) at P<0.05.